MGX (41) ALGS (26) ESLA (41) EVAX (58) ⌘ Pro Terminal →

Genenta Science S.p.A. (GNTA) — RQD Stock Rating Cockpit

$0.62 +2.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.62

Genenta Science S.p.A. (GNTA) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $29.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.62 (+0.26%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GNTA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY GNTA SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$0.79-13.9% Next Q

Q2 (-2Q)

Grade B-$0.68-7.4% Next Q

Q3 (-1Q)

Grade C+$0.63-1.6% Next Q

Current

Grade C$0.62+0.7% Hist 90D α

Trajectory: B (70) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GNTA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, GNTA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.79) or 200D SMA ($1.04) invalidates the momentum regime and cuts Target Base ($0.63) toward Bear Floor ($0.49).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GNTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GNTA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

36.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $1$0.62H: $3

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on GNTA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (62)

24/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like GNTA

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GNTA Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GNTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.68%▲ RESISTANCE BREAKOUT

2026-10-30O $0.62H $0.64L $0.60C $0.62VOL 67.2K

RES: $0.50SUP: $0.31SMA50: $0.79SMA200: $1.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GNTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GNTA Butterfly Map → + Track GNTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GNTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GNTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GNTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GNTA)

Health Care Rank #177 of 1016 ⚔️ MGX vs GNTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GNTA vs. MGX, ALGS, ESLA, EVAX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Genenta Science S.p.A. (GNTA) ranks #177 by composite RQD confidence (62/100, grade C) and #804 by equity capitalization ($29.9M). Within this direct 5-issuer industry benchmark cohort, GNTA leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GNTA ACTIVE Genenta Science S.p.A.	C	62/100	—	—	—	+2.48%	$29.9M	Benchmark Subject
MGX Metagenomi Therapeutics Inc.	D-	41/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-gnta →
ALGS Aligos Therapeutics Inc.	E	26/100	—	—	-35.0%	-2.71%	$31.4M	/algs-vs-gnta →
ESLA Estrella Immunopharma Inc.	D-	41/100	—	—	-35.0%	-11.32%	$31.7M	/esla-vs-gnta →
EVAX Evaxion A/S	D+	58/100	—	—	—	-0.96%	$27.8M	/evax-vs-gnta →

2. GNTA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Genenta Science S.p.A. (GNTA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $29.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. GNTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GNTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Genenta Science S.p.A. (NASDAQ: GNTA) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $0.62 (+2.48% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GNTA ranks #177 in composite RQD confidence.

How does GNTA compare to MGX and ALGS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GNTA carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MGX (Metagenomi Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $31.4M). Among the 5-stock peer group, GNTA leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GNTA?

For Genenta Science S.p.A. (GNTA), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and sector rank #177 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GNTA trading relative to its 50-day, 200-day, and 52-week technical levels?

GNTA last traded at $0.62 (+2.48% on volume of 153,196 shares), positioning the stock -21.52% below its 50-day simple moving average ($0.79) and -40.38% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.55 to $2.75, GNTA sits at the 3.2% percentile with a 14-day RSI of 36.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).

GNTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GNTA stock right now?

Genenta Science S.p.A. (GNTA) currently earns a Roarable Rating of C (Hold — HOLD) with 62/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is GNTA's 12-month price target and RQD AI Jury consensus?

GNTA's 12-month base price target is $0.63 (range $0.49 to $2.89), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GNTA RQD Cockpit GNTA 12M Forecast GNTA Earnings & Move GNTA Dividends & DRIP GNTA Insiders & 13F GNTA Whale Options GNTA Profit Sankey GNTA News & Why